# Nexentis Technologies Inc.: financial statements, quarterly

NXTS · Nasdaq · CIK 1789192 · [Healthcare](/sectors/healthcare.md) · fiscal year ends Dec 31

Pages: [Overview](/companies/nxts.md) · [Financials](/companies/nxts/financials.md) · [Filings](/companies/nxts/filings.md) · [Insiders](/companies/nxts/insiders.md)

Standardized line items from XBRL company facts. Each value links to its filing; d marks a value derived from year-to-date figures. Other view: [annual](/companies/nxts/financials.md?period=annual).

## Income statement

| Line item | Unit | Q3 FY2023 (2023-09-30) | Q4 FY2023 (2023-12-31) | Q1 FY2024 (2024-03-31) | Q2 FY2024 (2024-06-30) | Q3 FY2024 (2024-09-30) | Q4 FY2024 (2024-12-31) | Q1 FY2025 (2025-03-31) | Q2 FY2025 (2025-06-30) | Q3 FY2025 (2025-09-30) | Q4 FY2025 (2025-12-31) | Q1 FY2026 (2026-03-31) | Q2 FY2026 (2026-06-30) |
| --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Revenue | $m | [0.0 d](/filings/0001493152-24-045890.md) | [0.1 d](/filings/0001641172-25-001513.md) | [0.0](/filings/0001641172-25-010883.md) | [0.0](/filings/0001493152-25-011990.md) | [0.0](/filings/0001493152-25-022355.md) | [0.1 d](/filings/0001641172-25-001513.md) | [0.1](/filings/0001641172-25-010883.md) | [0.0 d](/filings/0001493152-25-011990.md) | [0.0](/filings/0001493152-25-022355.md) | not reported | not reported | not reported |
| Cost of revenue | $m | [0.0 d](/filings/0001493152-24-045890.md) | [(0.0) d](/filings/0001641172-25-001513.md) | [0.0](/filings/0001641172-25-010883.md) | [0.0](/filings/0001493152-25-011990.md) | [0.1](/filings/0001493152-25-022355.md) | [0.1 d](/filings/0001641172-25-001513.md) | [0.0](/filings/0001641172-25-010883.md) | [0.0](/filings/0001493152-25-011990.md) | [0.0](/filings/0001493152-25-022355.md) | not reported | not reported | not reported |
| Gross profit | $m | [(0.0) d](/filings/0001493152-24-045890.md) | [0.1 d](/filings/0001641172-25-001513.md) | [0.0](/filings/0001641172-25-010883.md) | [0.0](/filings/0001493152-25-011990.md) | [(0.1)](/filings/0001493152-25-022355.md) | [0.1 d](/filings/0001641172-25-001513.md) | [0.1](/filings/0001641172-25-010883.md) | [(0.0)](/filings/0001493152-25-011990.md) | [0.0 d](/filings/0001493152-25-022355.md) | not reported | not reported | not reported |
| Research and development | $m | [1.7](/filings/0001493152-24-045890.md) | [0.1 d](/filings/0001641172-25-001513.md) | [0.1](/filings/0001641172-25-010883.md) | [0.0](/filings/0001493152-25-011990.md) | [0.0](/filings/0001493152-25-022355.md) | [0.3 d](/filings/0001641172-25-001513.md) | [0.0](/filings/0001641172-25-010883.md) | [0.0](/filings/0001493152-25-011990.md) | [0.1](/filings/0001493152-25-022355.md) | [0.1 d](/filings/0001493152-26-014183.md) | [0.3](/filings/0001493152-26-023107.md) | [0.4](/filings/0001493152-26-037757.md) |
| Operating income | $m | [(2.9)](/filings/0001493152-24-045890.md) | [(2.1) d](/filings/0001641172-25-001513.md) | [(0.9)](/filings/0001641172-25-010883.md) | [(0.8)](/filings/0001493152-25-011990.md) | [(1.4)](/filings/0001493152-25-022355.md) | [(0.2) d](/filings/0001493152-26-014183.md) | [(0.5)](/filings/0001493152-26-023107.md) | [(2.6)](/filings/0001493152-26-037757.md) | [(1.3)](/filings/0001493152-25-022355.md) | [0.5 d](/filings/0001493152-26-014183.md) | [(8.2)](/filings/0001493152-26-023107.md) | [(1.9)](/filings/0001493152-26-037757.md) |
| Income tax | $m | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | [(0.0)](/filings/0001493152-26-023107.md) | [(0.0)](/filings/0001493152-26-037757.md) |
| Net income | $m | [(2.4)](/filings/0001493152-24-045890.md) | [(1.7) d](/filings/0001641172-25-001513.md) | [(0.8)](/filings/0001641172-25-010883.md) | [(0.8)](/filings/0001493152-25-011990.md) | [(2.3)](/filings/0001493152-25-022355.md) | [(1.4) d](/filings/0001493152-26-014183.md) | [(1.2)](/filings/0001493152-26-023107.md) | [(4.5)](/filings/0001493152-26-037757.md) | [0.4](/filings/0001493152-25-022355.md) | [1.3 d](/filings/0001493152-26-014183.md) | [(6.6)](/filings/0001493152-26-023107.md) | [(11.1)](/filings/0001493152-26-037757.md) |
| Diluted EPS | $ per share | [(1.78)](/filings/0001493152-24-045890.md) | not reported | [(0.26)](/filings/0001641172-25-010883.md) | [(0.23)](/filings/0001493152-24-032148.md) | [(0.39)](/filings/0001493152-24-045890.md) | not reported | [(85.25)](/filings/0001493152-26-023107.md) | [(44.26)](/filings/0001493152-26-037757.md) | [0.97](/filings/0001493152-25-022355.md) | not reported | [(10.74)](/filings/0001493152-26-023107.md) | [(13.66)](/filings/0001493152-26-037757.md) |
| Basic EPS | $ per share | [(1.78)](/filings/0001493152-24-045890.md) | not reported | [(0.26)](/filings/0001641172-25-010883.md) | [(0.23)](/filings/0001493152-25-011990.md) | [(14.27)](/filings/0001493152-25-022355.md) | not reported | [(18.00)](/filings/0001493152-26-023107.md) | [(44.26)](/filings/0001493152-26-037757.md) | [0.45](/filings/0001493152-25-022355.md) | not reported | [(10.74)](/filings/0001493152-26-023107.md) | [(13.66)](/filings/0001493152-26-037757.md) |

- Revenue: us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
- Cost of revenue: us-gaap:CostOfGoodsAndServicesSold
- Gross profit: us-gaap:GrossProfit
- Research and development: us-gaap:ResearchAndDevelopmentExpense
- Operating income: us-gaap:OperatingIncomeLoss
- Income tax: us-gaap:IncomeTaxExpenseBenefit
- Net income: us-gaap:NetIncomeLoss
- Diluted EPS: us-gaap:EarningsPerShareDiluted
- Basic EPS: us-gaap:EarningsPerShareBasic

## Balance sheet

| Line item | Unit | Q3 FY2023 (2023-09-30) | FY2023 (2023-12-31) | Q1 FY2024 (2024-03-31) | Q2 FY2024 (2024-06-30) | Q3 FY2024 (2024-09-30) | FY2024 (2024-12-31) | Q1 FY2025 (2025-03-31) | Q2 FY2025 (2025-06-30) | Q3 FY2025 (2025-09-30) | FY2025 (2025-12-31) | Q1 FY2026 (2026-03-31) | Q2 FY2026 (2026-06-30) |
| --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Cash and equivalents | $m | [1.9](/filings/0001493152-23-041078.md) | [4.4](/filings/0001641172-25-001513.md) | [3.5](/filings/0001493152-24-019822.md) | [4.5](/filings/0001493152-24-032148.md) | [2.7](/filings/0001493152-24-045890.md) | [1.9](/filings/0001493152-26-014183.md) | [2.7](/filings/0001641172-25-010883.md) | [3.1](/filings/0001493152-25-011990.md) | [6.0](/filings/0001493152-25-022355.md) | [3.8](/filings/0001493152-26-037757.md) | [4.3](/filings/0001493152-26-023107.md) | [7.6](/filings/0001493152-26-037757.md) |
| Current assets | $m | [2.8](/filings/0001493152-23-041078.md) | [5.5](/filings/0001641172-25-001513.md) | [4.4](/filings/0001493152-24-019822.md) | [5.5](/filings/0001493152-24-032148.md) | [3.4](/filings/0001493152-24-045890.md) | [3.5](/filings/0001493152-26-014183.md) | [4.3](/filings/0001641172-25-010883.md) | [5.0](/filings/0001493152-25-011990.md) | [8.7](/filings/0001493152-25-022355.md) | [6.0](/filings/0001493152-26-037757.md) | [8.2](/filings/0001493152-26-023107.md) | [10.4](/filings/0001493152-26-037757.md) |
| Total assets | $m | [5.3](/filings/0001493152-23-041078.md) | [7.2](/filings/0001641172-25-001513.md) | [6.3](/filings/0001493152-24-019822.md) | [7.5](/filings/0001493152-24-032148.md) | [5.8](/filings/0001493152-24-045890.md) | [5.5](/filings/0001493152-26-014183.md) | [7.4](/filings/0001641172-25-010883.md) | [7.8](/filings/0001493152-25-011990.md) | [11.0](/filings/0001493152-25-022355.md) | [20.4](/filings/0001493152-26-037757.md) | [16.4](/filings/0001493152-26-023107.md) | [18.7](/filings/0001493152-26-037757.md) |
| Current liabilities | $m | [0.6](/filings/0001493152-23-041078.md) | [0.8](/filings/0001641172-25-001513.md) | [0.6](/filings/0001493152-24-019822.md) | [1.6](/filings/0001493152-24-032148.md) | [0.5](/filings/0001493152-24-045890.md) | [0.9](/filings/0001493152-26-014183.md) | [1.0](/filings/0001641172-25-010883.md) | [1.1](/filings/0001493152-25-011990.md) | [2.1](/filings/0001493152-25-022355.md) | [1.4](/filings/0001493152-26-037757.md) | [1.7](/filings/0001493152-26-023107.md) | [2.8](/filings/0001493152-26-037757.md) |
| Total liabilities | $m | [0.6](/filings/0001493152-23-041078.md) | [0.8](/filings/0001641172-25-001513.md) | [0.6](/filings/0001493152-24-019822.md) | [1.6](/filings/0001493152-24-032148.md) | [0.5](/filings/0001493152-24-045890.md) | [0.9](/filings/0001493152-26-014183.md) | [3.7](/filings/0001641172-25-010883.md) | [2.2](/filings/0001493152-25-011990.md) | [2.4](/filings/0001493152-25-022355.md) | [4.7](/filings/0001493152-26-037757.md) | [3.5](/filings/0001493152-26-023107.md) | [16.9](/filings/0001493152-26-037757.md) |
| Long-term debt | $m | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported |
| Current portion of debt | $m | not reported | not reported | not reported | not reported | not reported | not reported | [0.0](/filings/0001641172-25-010883.md) | [1.2](/filings/0001493152-25-011990.md) | [1.2](/filings/0001493152-25-022355.md) | [1.4](/filings/0001493152-26-014183.md) | not reported | not reported |
| Short-term borrowings | $m | not reported | not reported | not reported | [1.2](/filings/0001493152-24-032148.md) | not reported | not reported | not reported | not reported | [1.1](/filings/0001493152-25-022355.md) | [0.7](/filings/0001493152-26-037757.md) | [0.4](/filings/0001493152-26-023107.md) | [0.2](/filings/0001493152-26-037757.md) |
| Shareholders' equity | $m | [4.6](/filings/0001493152-23-041078.md) | [6.5](/filings/0001641172-25-001513.md) | [5.8](/filings/0001493152-24-019822.md) | [6.0](/filings/0001493152-24-032148.md) | [5.4](/filings/0001493152-24-045890.md) | [4.7](/filings/0001493152-26-014183.md) | [3.9](/filings/0001641172-25-010883.md) | [5.8](/filings/0001493152-25-011990.md) | [8.9](/filings/0001493152-25-022355.md) | [16.0](/filings/0001493152-26-037757.md) | [13.0](/filings/0001493152-26-023107.md) | [1.9](/filings/0001493152-26-037757.md) |

- Cash and equivalents: us-gaap:CashAndCashEquivalentsAtCarryingValue
- Current assets: us-gaap:AssetsCurrent
- Total assets: us-gaap:Assets
- Current liabilities: us-gaap:LiabilitiesCurrent
- Total liabilities: us-gaap:Liabilities
- Long-term debt: not reported
- Current portion of debt: us-gaap:DebtCurrent
- Short-term borrowings: us-gaap:ShortTermBorrowings
- Shareholders' equity: us-gaap:StockholdersEquity

## Cash flow

| Line item | Unit | Q3 FY2023 (2023-09-30) | Q4 FY2023 (2023-12-31) | Q1 FY2024 (2024-03-31) | Q2 FY2024 (2024-06-30) | Q3 FY2024 (2024-09-30) | Q4 FY2024 (2024-12-31) | Q1 FY2025 (2025-03-31) | Q2 FY2025 (2025-06-30) | Q3 FY2025 (2025-09-30) | Q4 FY2025 (2025-12-31) | Q1 FY2026 (2026-03-31) | Q2 FY2026 (2026-06-30) |
| --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Operating cash flow | $k | [(624) d](/filings/0001493152-24-045890.md) | [(975) d](/filings/0001641172-25-001513.md) | [(1,008)](/filings/0001641172-25-010883.md) | [(1,028) d](/filings/0001493152-25-011990.md) | [(891) d](/filings/0001493152-25-022355.md) | [(492) d](/filings/0001493152-26-014183.md) | [(809)](/filings/0001493152-26-023107.md) | [(528) d](/filings/0001493152-26-037757.md) | [(974) d](/filings/0001493152-25-022355.md) | [(1,497) d](/filings/0001493152-26-014183.md) | [(1,419)](/filings/0001493152-26-023107.md) | [(539) d](/filings/0001493152-26-037757.md) |
| Capital expenditure | $k | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | [71.0](/filings/0001493152-26-023107.md) | [1.0 d](/filings/0001493152-26-037757.md) |

- Operating cash flow: us-gaap:NetCashProvidedByUsedInOperatingActivities
- Capital expenditure: us-gaap:PaymentsToAcquirePropertyPlantAndEquipment

## Shares

| Line item | Unit | Q3 FY2022 (2022-09-30) | Q1 FY2023 (2023-03-31) | Q2 FY2023 (2023-06-30) | Q3 FY2023 (2023-09-30) | Q1 FY2024 (2024-03-31) | Q2 FY2024 (2024-06-30) | Q3 FY2024 (2024-09-30) | Q1 FY2025 (2025-03-31) | Q2 FY2025 (2025-06-30) | Q3 FY2025 (2025-09-30) | Q1 FY2026 (2026-03-31) | Q2 FY2026 (2026-06-30) |
| --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Diluted shares (weighted) | thousands of shares | [558](/filings/0001493152-23-041078.md) | [696](/filings/0001493152-24-019822.md) | [1,027](/filings/0001493152-24-032148.md) | [1,331](/filings/0001493152-24-045890.md) | [2,961](/filings/0001641172-25-010883.md) | [3,409](/filings/0001493152-24-032148.md) | [5,820](/filings/0001493152-24-045890.md) | [102](/filings/0001493152-26-023107.md) | [102](/filings/0001493152-26-037757.md) | [967](/filings/0001493152-25-022355.md) | [613](/filings/0001493152-26-023107.md) | [816](/filings/0001493152-26-037757.md) |

- Diluted shares (weighted): us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding

Shares outstanding: 1,453,333 at 2026-08-13, from the cover of the [10-Q filed 2026-08-13](/filings/0001493152-26-037757.md) (dei:EntityCommonStockSharesOutstanding).

Source: SEC EDGAR, XBRL company facts. Last ingested by Listed: Oct 24, 2026, 15:47 ET. No prices; not investment advice.